Τίτλος:
Canagliflozin: A new hope in the antidiabetic armamentarium
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Canagliflozin-with the patent number WO2011142478A1- belongs to a novel class of antidiabetic drugs known as SGLT2 inhibitors, which has been approved by FDA in March 2013. This medication acts through the inhibition of glucose reabsorption in the kidney resulting in glucosuria and thus lowering of glucose blood levels. There are several phase III clinical ongoing trials involving this new class of medications. So far promising results have been shown. This review article summarizes current knowledge regarding the novel SGLT2 inhibitor canagliflozin and its future perspectives in the treatment of type 2 diabetes mellitus. © 2013 Bentham Science Publishers.
Συγγραφείς:
Katsi, V.K.
Michalakeas, C.A.
Grassos, C.E.
Vamvakou, G.D.
Lekakis, J.P.
Tousoulis, D.
Stefanadis, C.I.
Makris, T.K.
Kallikazaros, I.E.
Περιοδικό:
Recent Patents on Cardiovascular Drug Discovery
Εκδότης:
Bentham Science Publishers B.V.
Λέξεις-κλειδιά:
angiotensin receptor antagonist; antidiabetic agent; canagliflozin; dipeptidyl carboxypeptidase inhibitor; diuretic agent; glimepiride; glucose; hemoglobin A1c; high density lipoprotein; insulin; metformin; potassium; sitagliptin; sodium; sodium glucose cotransporter 2 inhibitor; antidiabetic agent; canagliflozin; glucoside; sodium glucose cotransporter 2; thiophene derivative, antidiabetic activity; article; caloric intake; cardiovascular disease; cardiovascular risk; diabetic ketoacidosis; drug efficacy; drug mechanism; drug safety; end stage renal disease; food and drug administration; glucose absorption; glucose blood level; glucosuria; glycemic control; heart infarction; human; insulin release; kidney function; monotherapy; mycosis; non insulin dependent diabetes mellitus; orthostatic hypotension; osmotic diuresis; pleiotropy; priority journal; severe renal impairment; systolic blood pressure; urinary tract infection; urogenital tract infection; weight reduction; antagonists and inhibitors; clinical trial (topic); Diabetes Mellitus, Type 2, Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Thiophenes
DOI:
10.2174/1574890108666131213100613
